Asia Pacific Organoids Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Asia Pacific organoids market size is expected to reach US$ 2,327.10 million by 2031 from US$ 419.14 million in 2023. The market is estimated to record a CAGR of 23.9% from 2023 to 2031.

Executive Summary and Asia Pacific Organoids Market Analysis:

The Asia Pacific organoids market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. The market is likely to continue growing at the fastest rate during the forecast period owing to factors such as increasing incidences of cancer, growing demand for gene mutation and cancer research, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoids products, and increased funding for organoids research.

Asia Pacific Organoids Market Strategic Insights

Get more information on this report Request Free Sample PDF

Asia Pacific Organoids Market Segmentation Analysis

Key segments that contributed to the derivation of the Asia Pacific organoids market analysis are type, application, source, offering, and method.

• Based on type, the Asia Pacific organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine held the largest share of the market in 2023.
• Based on application, the Asia Pacific organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease held the largest share of the market in 2023.
• Based on source, the Asia Pacific organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells held a larger share of the market in 2023.
• Based on offering, the Asia Pacific organoids market is segmented into instruments, consumables, and services. The consumables held the largest share of the market in 2023. The instruments segment is further subsegmented into devices and equipment. The consumables segment is further subsegmented into sensors and others.
• Based on method, the Asia Pacific organoids market is segmented into micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion, and others. The hanging drop held the largest share of the market in 2023.

Asia Pacific Organoids Market Outlook

Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs that are tailored to the individual patient based on the anticipated response or disease risk. 

Across Asia, the rise of personalized medicine is significantly accelerating the development and implementation of organoid technologies. In China, companies such as ACCURATE International Biotechnology have established one of the world’s largest tumor organoid platforms, which houses over 5,000 models to support patient-specific drug testing. Collaborative laboratories launched in 2022 with leading institutions like the University of Macau have further enhanced research on disease modeling and drug responses. Further, in Japan, universities such as Kyushu and Nagoya have integrated artificial intelligence with organoid development, achieving up to 70% accuracy in selecting high-quality organoids for therapeutic use. Japanese researchers are also investigating gene-edited organoids to study liver and neurological disorders.

In South Korea, the 2024 Organoid Developer Conference held in Pangyo showcased applications in regenerative medicine, with experts such as Dr. Ryuichi Okamoto discussing the use of organoids in treating ulcerative colitis. Meanwhile, Singapore is emerging as a regional hub for innovation. In 2023, Next&Bio signed a memorandum of understanding with the Cancer Science Institute of Singapore to co-develop a cancer organoid bank, which will enable more effective, patient-matched oncology therapies.

Pharmacists play an essential role in propelling the demand for personalized medicines as they proactively create awareness about precision medicine. The increasing demand has persuaded pharmaceutical enterprises to develop more tailored treatments to make medicines safer and more effective. Personalized cancer medicine revolves around tailoring effective therapeutic strategies for each patient according to the genomic characterization of their tumor. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in preclinical settings. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine to investigate treatments based on gene–drug associations, identify new therapies, and predict patient outcomes. The use of personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. The preservation of the molecular and cellular composition of an original tumor is a significant advantage of tumor organoid models over pre-existing models. Thus, the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens, fuels the organoids market growth.

Asia Pacific Organoids Market Country Insights

Based on country, the Asia Pacific organoids market comprises Japan, China, India, South Korea, Australia, Southeast Asia, and the Rest of Asia Pacific. China held the largest share in 2023.

The organoids market growth in China is primarily attributed to discoveries driven by research and development and the popularity of personalized medicine. One of the most considerable advancements in cancer research in the last decade has been the development of tumor organoids: high-tech 3D cell cultures that reproduce mini organs in vitro through 3D modeling and mimic a few specific structures and functions of tumors in a particular organ. This technology enables the scientific community to study a wide range of tissues and organs affected by tumors.

The rise in demand for gene mutation and cancer research is likely to also support the market expansion in China. For instance, in September 2020, Hubrecht Organoid Technology (HUB) and BGI-Qingdao inked a Memorandum of Understanding (MoU) to establish a joint Next Generation Diagnostics (NGD) center to improve personalized care, better treatments and cures, and faster development of novel, safe medicines in China. With their complementary expertise and technology, HUB and BGI planned to develop and implement HUB Organoid Technology further as predictive diagnostic tests for treatment responses with a focus on cancer. Similarly, in October 2020, IBP Laboratory was introduced to model brain organoids and cultivation technologies.

Increasing grants for research and development in stem cell research are likely to encourage research and development associated with organoids during the forecast period. For instance, in June 2024, researchers from Tianjin University and the Southern University of Science and Technology developed an open-source on-chip brain-computer interface system—MetaBOC. It is a technology that uses an in vitro cultured brain (brain organoids) coupled with an electrode chip to achieve information interaction from external sources through encoding and decoding, as well as stimulation feedback.

Asia Pacific Organoids Market Report Highlights

Asia Pacific Organoids Market Company Profiles

Some of the key players operating in the market STEMCELL Technologies Inc; Molecular Devices, LLC.; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA; InSphero; ACRO Biosystems; Bio-Techne Corp; SUN bioscience SA; ORGANOID SCIENCES Co., Ltd.; Crown Bioscience Inc; Sartorius AG; 3D Biotek LLC; Prellis Biologics Inc.; 3Dnamics Inc.; and Cellesce Ltd, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Organoids Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Asia Pacific Organoids Market Country and Regional Insights